Earnings summaries and quarterly performance for Anteris Technologies Global.
Executive leadership at Anteris Technologies Global.
Board of directors at Anteris Technologies Global.
Research analysts covering Anteris Technologies Global.
Recent press releases and 8-K filings for AVR.
Anteris Technologies (AVR) Highlights Operational Expansion, Clinical Progress, and Strategic U.S. Re-domiciliation at 2025 AGM
AVR
Product Launch
New Projects/Investments
Executive Compensation
- Anteris Technologies (AVR) reported significant progress with its DurAVR valve, demonstrating a 3% patient prosthesis mismatch (PPM) rate in trials, which is substantially lower than the 30%+ observed with traditional market-leading valves.
- The company has tripled its manufacturing capacity by adding a second clean room and is ahead of schedule for pivotal trial capacity, indicating readiness for commercialization.
- Anteris strategically re-domiciled to the U.S. to enhance access to capital and liquidity, with 66% of its operations now based in the U.S., attracting specialized healthcare funds.
- The 2025 AGM agenda includes proposals for the election of directors and the approval of significant RSU grants, notably 1 million RSUs to CEO Wayne Paterson.
Dec 3, 2025, 11:00 PM
Anteris Technologies Updates on DurAVR Progress and Financial Strategy at FY 2025 AGM
AVR
Product Launch
New Projects/Investments
- Anteris Technologies' DurAVR valve demonstrates clinical superiority, achieving a 3% patient prosthesis mismatch (PPM) rate in 100 patients, significantly lower than competitors' 30%+, and is positioned as a leader in TAVR science.
- The company is ahead of its goals for pivotal trial capacity and has expanded its logistics and distribution center by three to four times to prepare for increased product volume and commercialization.
- Anteris re-domiciled to the U.S. to enhance access to capital and facilitate potential future deals, noting a 1,000% increase in liquidity on Nasdaq compared to the ASX.
- The estimated capital required to complete recruitment for the Paradigm study by Q4 2026 is $120 million-$125 million, with the company receiving $25,000 per device in the U.S. for reimbursement.
- Despite a challenging market for small-cap MedTechs, analysts maintain a "buy" consensus for Anteris, with an average price target of $15-$20.
Dec 3, 2025, 11:00 PM
Anteris (AVR) Provides Business Update and Clinical Data Highlights at 2025 Annual Meeting
AVR
Product Launch
New Projects/Investments
Board Change
- Anteris reported significant clinical results from its paradigm trial, demonstrating a 3% rate of Patient Prosthesis Mismatch (PPM) in 100 patients, which is substantially lower than the 10-13% observed with the best available valves and over 30% for traditional market-leading valves.
- The company has secured FDA approval and European approval for its product, and the Paradigm study has commenced largely on schedule.
- Anteris estimates requiring $120 million - $125 million in capital to fund recruitment through Q4 2026, and receives $25,000 per device in reimbursement in the US.
- The company has expanded its logistics and distribution capabilities for global shipping, with product volume expected to expand tremendously in the next six months.
Dec 3, 2025, 11:00 PM
Anteris Technologies Global Corp. Announces Q3 2025 Financials and Regulatory Milestones
AVR
Earnings
New Projects/Investments
- Anteris Technologies Global Corp. reported financial results for the quarter ended September 30, 2025, including $16.8 million in R&D expenses and $5.8 million in selling, general, and administrative expenses for the quarter.
- As of September 30, 2025, the company held $9.1 million in cash and cash equivalents. Net operating cash outflows for the nine months ended September 30, 2025, were $59.3 million.
- The company announced FDA approval to commence U.S. recruitment for its PARADIGM Trial in November 2025, and the first PARADIGM patients were treated in Denmark in October 2025.
- Of the US$80.0 million net proceeds from its December 2024 IPO, US$52.7 million was used for DurAVR® THV development and the Pivotal Trial, and US$18.3 million net for debt repayment, working capital, and general corporate purposes as of September 30, 2025.
Nov 12, 2025, 10:36 PM
Anteris Technologies Global Corp. Announces Equity Offering
AVR
New Projects/Investments
- Anteris Technologies Global Corp. entered into agreements on or about October 23, 2025, to sell 2,244,896 shares of common stock and accompanying five-year warrants at US$4.90 per share and warrant, and 2,788,064 CHESS Depositary Interests (CDIs) and accompanying five-year warrants at A$7.50 per CDI and warrant, with an expected aggregate gross proceeds of approximately US$25 million.
- The Common Stock Offering is anticipated to close around October 27, 2025, and the CDI Offering is expected to settle around October 30, 2025, both subject to customary closing conditions.
- The company is targeting the First Patient In (FPI) for its pivotal PARADIGM Trial in Q4 2025, following targeted IDE approval in the same quarter, aiming to address a TAVR market opportunity forecasted to reach US$9.9 billion by 2028.
Oct 24, 2025, 9:10 PM
Anteris Technologies Global Corp. receives first European regulatory clearance for DurAVR® THV pivotal trial
AVR
New Projects/Investments
Product Launch
- Anteris Technologies Global Corp. (AVR) has received its first European regulatory clearance from the Danish Medicines Agency to initiate the DurAVR® Transcatheter Heart Valve (THV) global pivotal trial (PARADIGM Trial).
- Patient recruitment for the PARADIGM Trial in Danish centers is expected to commence in 4Q 2025.
- This multi-center global study will evaluate the safety and effectiveness of the DurAVR® THV compared to commercially available transcatheter aortic valve replacements (TAVRs), with planned expansion across the United States, Europe, and Canada.
- An Investigational Device Exemption (IDE) application for the U.S. is currently under review by the FDA, with approval anticipated in the near term.
Oct 15, 2025, 1:29 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more